January 21, 2014 -
According to the company, by analyzing incoming data using both visible light and infrared cameras in parallel, this innovative technology accurately identifies faces in most lighting conditions and is highly resistant to ID spoofing attacks using photos and videos.
The key to the system’s tolerance of diverse lighting conditions comes from its use of both visible light and infrared imaging. 20 points of comparison are made for face matching.
The system is also able to detect the difference between a live face, versus an image or video, as its ual-camera imaging system evaluates inputs for infrared heat signatures.
“This technology gives users high security without headaches,” Gilles Florey, KeyLemon co-founder and CEO said. “Since our dual-camera face ID system operates continuously, in the background and without any interaction required, users forget it’s even there, protecting their data 24/7. And that’s always been a top priority for us. In our view, technology that gets out of your way is the best technology of all.”
“Secure, fast and reliable face identification is an excellent use of 3D technology and our DepthSense camera,” Eric Krzeslo, chief marketing officer at SoftKinetic said. “By combining 3D and infrared (IR) data with face recognition technology, individuals and enterprises who require the highest level of security now have an excellent solution.”
“The uses for this technology are nearly limitless, from consumer devices to enterprise, automotive, medical, online banking, and countless other applications,” Florey said. “We are very excited to partner with SoftKinetic in bringing this new face ID system to our customers, and we can’t wait to see how they’ll put it to work in their industries.”
Reported previously, KeyLemon’s facial recognition software was recently licensed by Visteon to develop an intelligent in-car experience for drivers.
In September 2013, KeyLemon closed a significant $1.5 million Series A round of funding. The investment, the company’s first external funding, was co-led by Debiopharm Investment and Swisscom Ventures.